Cognition Therapeutics CGTX Stock
Cognition Therapeutics Price Chart
Cognition Therapeutics CGTX Financial and Trading Overview
| Cognition Therapeutics stock price | 0.44 USD |
| Previous Close | 2.88 USD |
| Open | 2.95 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 1000 |
| Day's Range | 2.87 - 3.1 USD |
| 52 Week Range | 1.07 - 6.27 USD |
| Volume | 72.01K USD |
| Avg. Volume | 85.52K USD |
| Market Cap | 87.54M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.86 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.75 USD |
CGTX Valuation Measures
| Enterprise Value | 46.74M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.669643 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.4468086 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.086 |
Trading Information
Cognition Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 80.12% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 6.27 USD |
| 52 Week Low | 1.07 USD |
| 50-Day Moving Average | 2.03 USD |
| 200-Day Moving Average | 1.96 USD |
CGTX Share Statistics
| Avg. Volume (3 month) | 85.52K USD |
| Avg. Daily Volume (10-Days) | 128.25K USD |
| Shares Outstanding | 29.28M |
| Float | 18.85M |
| Short Ratio | 0.63 |
| % Held by Insiders | 7.79% |
| % Held by Institutions | 43.47% |
| Shares Short | 61.23K |
| Short % of Float | 0.33% |
| Short % of Shares Outstanding | 0.20% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -51.63% |
| Return on Equity (ttm) | -56.15% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -43025000 USD |
| Net Income Avi to Common (ttm) | -23731000 USD |
| Diluted EPS (ttm) | -0.93 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 38.81M USD |
| Total Cash Per Share (mrq) | 1.33 USD |
| Total Debt (mrq) | 1.24M USD |
| Total Debt/Equity (mrq) | 3.45 USD |
| Current Ratio (mrq) | 5.734 |
| Book Value Per Share (mrq) | 1.222 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -18250000 USD |
| Levered Free Cash Flow (ttm) | -21918500 USD |
Profile of Cognition Therapeutics
| Country | United States |
| State | NY |
| City | Purchase |
| Address | 2500 Westchester Avenue |
| ZIP | 10577 |
| Phone | 412 481 2210 |
| Website | https://www.cogrx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 22 |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.
Q&A For Cognition Therapeutics Stock
What is a current CGTX stock price?
Cognition Therapeutics CGTX stock price today per share is 0.44 USD.
How to purchase Cognition Therapeutics stock?
You can buy CGTX shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cognition Therapeutics?
The stock symbol or ticker of Cognition Therapeutics is CGTX.
Which industry does the Cognition Therapeutics company belong to?
The Cognition Therapeutics industry is Biotechnology.
How many shares does Cognition Therapeutics have in circulation?
The max supply of Cognition Therapeutics shares is 62.48M.
What is Cognition Therapeutics Price to Earnings Ratio (PE Ratio)?
Cognition Therapeutics PE Ratio is now.
What was Cognition Therapeutics earnings per share over the trailing 12 months (TTM)?
Cognition Therapeutics EPS is -0.86 USD over the trailing 12 months.
Which sector does the Cognition Therapeutics company belong to?
The Cognition Therapeutics sector is Healthcare.
Cognition Therapeutics CGTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ Global Market Composite NQGM | 1839.71 USD — |
-3.16
|
— — | 1825.54 USD — | 1881.06 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
- {{ link.label }} {{link}}